Navigation Links
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Date:9/10/2009

WATERTOWN, Mass., Sept. 10 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

"We appreciate the opportunity to share some of the results from our work with this very powerful and ground-breaking chemistry platform," stated Mr. Guy Macdonald, President and CEO of Tetraphase Pharmaceuticals. "This enabling chemistry technology dramatically expands the chemical diversity of tetracyclines and is highly versatile, providing compounds with possibilities for IV and oral dosing routes and activity against multiple drug-resistant strains."

The oral presentation will be given in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines", as follows:

September 14(th) (9:00 a.m. - 9:15 a.m., Poster Session 142)

  • Presentation Number F1-1219 - Oral Antibacterial Activity of a Novel Pentacycline

The posters will be presented in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines" as follows:

September 14(th) (11:15 a.m. - 1:15 p.m., Poster Session 166)

  • Presentation Number F1-1514: Synthesis and Antibacterial Activities of Aza Tetracyclines: A Novel Class of Tetracycline Analogs

  • Presentation Number F1-1515: In Vitro and In Vivo Activities of Novel Broad-Spectrum 8-Aza Tetracyclines

  • Presentation Number F1-1516: Synthesis and Antibacterial Activities of Pentacyclines: A Novel Class of Tetracycline Analogs

Copies of the oral presentation and the posters will be available at ICAAC and on the Tetraphase website (www.tphase.com) following ICAAC.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
2. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
3. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
4. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
5. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
7. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
11. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that the ... provides capabilities for managing and processing genomic and health data at petabyte scale. ... collecting and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. ...
(Date:2/10/2016)... Vancouver, BC (PRWEB) , ... February 09, 2016 ... ... and design services and current winner of the Highest Overall Customer Rating ... certification in all of its business units across the USA, Canada, Mexico and ...
(Date:2/9/2016)... ... ... Date and time: March 1, 2016, 5:30 p.m. to ... of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The Baruch ... house for participants to learn about a new Master of Biomedical Science (MBS) ...
(Date:2/9/2016)... ... , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre has joined the firm ... new accounts and work closely with existing Tunnell clients throughout Europe to ensure their ... clients more than 15 years of experience in the pharmaceutical industry, a thorough knowledge ...
Breaking Biology Technology:
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):